Replies to post #67828 on Biotech Values

[DewDiligence]

SVNT off 73% – you can tell from the nondescript
language in the PR header that the news is not good:

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

http://biz.yahoo.com/prnews/081027/ny41686.html

[DewDiligence]

RDEA closed off 17% — perhaps guilt by association with SVNT?